Celldex Therapeutics, Inc.
NASDAQCelldex Therapeutics heads into its August 3 earnings with a crowded analysts' desk, a stock down nearly 7% on the week, and fresh target-price cuts arriving from multiple directions on the same day. The most striking development this week is the coordinated pullback from the Street. Four analyst firms trimmed price targets on July 22 alone — Wells Fargo, Morgan Stanley, Cantor…
Snapshot as of 16 Aug 2026
Celldex Therapeutics heads into its August 3 earnings with a crowded analysts' desk, a stock down nearly 7% on the week, and fresh target-price cuts arriving from multiple directions on the same day. The most striking…
Celldex Therapeutics heads into its June 25 earnings with short sellers rebuilding positions, UBS lifting its target on the day, and the stock still down sharply from its month-ago levels. The most telling tension this…
Celldex Therapeutics enters the post-earnings stretch with a striking split: short sellers are unwinding at pace while the analyst community shifts decisively more constructive, yet the stock is still down 5.5% on the…
Celldex Therapeutics reports Q1 2026 results on May 11 with short sellers maintaining a meaningful position — but the borrow market tells a story of fading conviction rather than escalating pressure. Short interest is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CLDX — free to start on ORTEX.
Sign up for free →Open CLDX on ORTEX